Sept. 6, 2012
-- Rosa & Co. LLC today announced that Dr. Malcolm Rowland, Professor Emeritus, University of Manchester, will present a webinar “Addressing drug development questions with physiologically based pharmacokinetics”
on Wednesday, September 19, 2012 at 12:00 - 1:00 pm EDT as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development”
, is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics, and other life science industries. This series is geared to illustrate the advantages and applicability of M&S in product discovery, development, and marketing programs.
According to Dr. Rowland, “Historically, pharmacokinetics has been descriptive and limited in its informativeness. Physiologically based pharmacokinetics (PBPK) and associated models offer a mechanistic, highly informative approach to the subject. The principles behind PBPK will be described and PBPK applications will be illustrated within the context of drug development, both in preclinical predictions of human PK and in clinical development, and within the context of addressing regulatory questions.”
Register for this free webinar at http://www.rosaandco.com/webinar
. After registering, a confirmation email will be sent with directions for joining the webinar. More information about the webinar series, an archive of past webinars, and a list of future webinar speakers may be found at http://www.rosaandco.com/
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/
pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/
More information can be found online at http://www.rosaandco.com
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.